Colgate-Palmolive Tom's of Maine $2.9M Settlement for Deceptive Toothpaste Marketing

This class action centers on claims that Colgate-Palmolive and its Tom’s of Maine brand allegedly used deceptive marketing on certain toothpaste products. The lawsuit, *Rabinowitz et al. v. Colgate-Palmolive Company et al.*, was filed in federal court in the Eastern District of New York and points to issues said to have arisen after an FDA inspection of the company’s Sanford, Maine facility. According to the settlement terms, the case involves a $2.9 million settlement fund and covers U.S. consumers who bought Tom’s of Maine toothpaste during the class period (November 21, 2020 through March 6, 2026), with claim requirements designed to make compensation easier for those who purchased one product and more specific for those who seek refunds for multiple items. The significance of the lawsuit is twofold: it challenges how toothpaste labels and promotional claims are presented to the public, and it tests whether company marketing may have misled customers about product characteristics or compliance concerns. Importantly for consumers, the settlement offers a path to recovery—either without proof using an average MSRP for one product per household or with proof through refund eligibility for up to three products. It also reflects broader pressure on consumer goods companies to ensure that advertising aligns with regulatory expectations, especially where the FDA oversees over-the-counter drug and health-related claims and expects manufacturers to maintain truthful, non-misleading statements in labeling and marketing. More widely, cases like this fit into a recurring pattern in the food, drug, and personal care industries, where disputes often arise from contested claims, enforcement actions, or compliance findings that consumers believe were communicated improperly. While this settlement is specific to Tom’s of Maine toothpaste marketing and the allegations tied to the Sanford inspection, the underlying theme—accountability for allegedly misleading consumer-facing health/product messaging—can have ripple effects by encouraging clearer compliance processes and more careful claim substantiation across the market, ultimately shaping how similar advertising disputes may play out in future litigation.